BR1015 clinical trials
Also written BR1015.
How each study uses BR1015 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the BR1015 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
10 studies that test it; most in 2025 (4)
| Year | Studies |
|---|---|
| 2023 | 2 |
| 2025 | 4 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 0
Studies
Open first, then newest update. How each study uses BR1015 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fed ConditionsNot yet recruitingPhase 1Boryung Pharmaceutical Co., LtdNCT07421388Written as BR1015-A
- A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fasting ConditionsNot yet recruitingPhase 1Boryung Pharmaceutical Co., LtdNCT07421401Written as BR1015-A
- A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fasting ConditionsNot yet recruitingPhase 1Boryung Pharmaceutical Co., LtdNCT07421375Written as BR1015-A
- A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fed ConditionsNot yet recruitingPhase 1Boryung Pharmaceutical Co., LtdNCT07421414Written as BR1015-A
- A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 Under Fasting ConditionsCompletedPhase 1Boryung Pharmaceutical Co., LtdNCT06744127Written as BR1015
- A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 in Healthy Volunteers Fed ConditionsCompletedPhase 1Boryung Pharmaceutical Co., LtdNCT06744062Written as BR1015
- A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fasting ConditionsCompletedPhase 1Boryung Pharmaceutical Co., LtdNCT06744426Written as BR1015
- A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fed ConditionsCompletedPhase 1Boryung Pharmaceutical Co., LtdNCT06744439Written as BR1015
- A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fasting Conditions in Healthy VolunteersCompletedPhase 1Boryung Pharmaceutical Co., LtdNCT06008028Written as BR1015
- A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy VolunteersCompletedPhase 1Boryung Pharmaceutical Co., LtdNCT06008015Written as BR1015